Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin protein ligase E3 component n-recognin 4 (UBR4) is a very large, multifunctional E3 and E4 ubiquitin ligase that plays a critical role in cellular protein quality control systems, including the N-end rule pathway and related degradation pathways[1][2][3][4][5]. UBR4 recognizes and ubiquitinates proteins with destabilizing N-terminal residues (N-degrons), facilitating their degradation primarily via the ubiquitin-proteasome system. It also works as an E4 ligase, amplifying ubiquitination signals by specifically extending lysine-48-linked ubiquitin chains on misfolded, aggregated, or otherwise unwanted proteins—frequently operating as part of multi-subunit complexes with cofactors such as KCMF1 and calmodulin[1][4]. UBR4 is involved in crucial stress-response pathways, including the clearance of oxidized proteins and regulation of stress-induced autophagy. It interacts with key cellular structures, functioning as both a cytoskeletal component in the cytoplasm and a chromatin scaffold in the nucleus[3][5]. UBR4 is essential for proteostasis in long-lived, metabolically active cells such as neurons and muscle cells; mutations or dysregulation of UBR4 have been linked to neurodegeneration, muscular atrophy, and cancer progression[2][3][4]. Its requirement in multiple protein quality control and cell surveillance mechanisms makes it a potential—but complicated—therapeutic target, as its inhibition could risk widespread proteostasis disruption. No drugs are currently known to directly modulate UBR4 in clinical use or trials[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin protein ligase E3 component n-recognin 4 (UBR4).